Answers are grounded in this paper and cite their sources.
Breast cancer is the most commonly diagnosed cancer in women worldwide, and value-based healthcare (VBHC) offers a framework to improve outcomes per unit of cost across its multidisciplinary care cycle, particularly in early-stage disease, where curative-intent treatment and long-term survivorship place patient-reported outcomes at the center of value. Despite broad endorsement, no review has systematically mapped the adoption of the components of the value agenda in breast cancer services worldwide. This scoping review followed Joanna Briggs Institute methodology and PRISMA-ScR reporting guidelines; PubMed, Embase, and Web of Science were searched in June 2026, supplemented by manual searching of organizational sources. Studies describing the application of VBHC to breast cancer were eligible; conventional economic evaluations and non-implementation studies were excluded. The value-agenda domains and the LEADER framework were used to identify how VBHC is being adopted. We included 12 studies (2014 to 2026), of which 11 described implemented programs, all in high-income settings: the Netherlands (n = 3), the United States (n = 2), Australia (n = 2), Taiwan (n = 1) and Spain (n = 3, two of them multicountry European studies). No programs from Latin America, Africa or South and Southeast Asia were identified. Outcome measurement was the most consistently implemented dimension: 64% of programs referenced the ICHOM standard set, 73% used additional validated instruments, and 73% embedded a culture of value delivery. Economic components were markedly underdeveloped: no program measured real costs using time-driven activity-based costing, and bundled payment was implemented in only two programs (18%). LEADER framework adherence was asymmetric, with accurate outcome data and measurement present in 91% of programs and effective agreements and risk mitigation in only 27% each. A structural gap between a consolidated measurement layer and an underdeveloped financing layer persisted across the twelve years analyzed. Advancing the field requires alignment between PROMs measurement programs with value-based payment initiatives in order to effectively measure the value these strategies deliver to healthcare systems.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: